Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stoycheva

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Biochemical and Biophysical Research Communications|April 4, 2021
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster modelKoen Vandyck, Rana Abdelnabi, Kusum Gupta, et al.
Patient Preference and Adherence|December 9, 2024
Association of Patients' Knowledge on the Disease and Its Management with Indicators of Disease Severity and Individual Characteristics in Patients with Chronic Obstructive Pulmonary Disease (COPD): Results from COSYCONET 2Carolina Fischer, Maria Siakavara, Peter Alter, et al.
Journal of Medicinal Chemistry|September 2, 2024
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASHKoen Vandyck, David C McGowan, Xuan G Luong, et al.
Mbio|January 10, 2023
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To NirmatrelvirDirk Jochmans, Cheng Liu, Kim Donckers, et al.
Antimicrobial Agents and Chemotherapy|October 1, 2008
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)Scott D Seiwert, Steven W Andrews, Yutong Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2009
HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivativesGuangyi Wang, Huoxing Lei, Xiaofang Wang, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
Nanoimpact|July 26, 2024
Next Generation Risk Assessment approaches for advanced nanomaterials: Current status and future perspectivesDanail Hristozov, Elena Badetti, Paolo Bigini, et al.
Nature Cancer|March 11, 2026
Impact of using artificial intelligence as a second reader in breast screening including arbitrationLucy M Warren, Jenny Venton, Kenneth C Young, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Biochemical and Biophysical Research Communications|April 4, 2021
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster modelKoen Vandyck, Rana Abdelnabi, Kusum Gupta, et al.
Patient Preference and Adherence|December 9, 2024
Association of Patients' Knowledge on the Disease and Its Management with Indicators of Disease Severity and Individual Characteristics in Patients with Chronic Obstructive Pulmonary Disease (COPD): Results from COSYCONET 2Carolina Fischer, Maria Siakavara, Peter Alter, et al.
Journal of Medicinal Chemistry|September 2, 2024
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASHKoen Vandyck, David C McGowan, Xuan G Luong, et al.
Mbio|January 10, 2023
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor <i>In Vitro</i> and Confer Resistance To NirmatrelvirDirk Jochmans, Cheng Liu, Kim Donckers, et al.
Antimicrobial Agents and Chemotherapy|October 1, 2008
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)Scott D Seiwert, Steven W Andrews, Yutong Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2009
HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivativesGuangyi Wang, Huoxing Lei, Xiaofang Wang, et al.
The Journal of Antimicrobial Chemotherapy|July 4, 2025
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TBSimon E Koele, Krista Stoycheva, Cyprian Mtweve, et al.
The Lancet. Infectious Diseases|July 11, 2025
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trialNorbert Heinrich, Christina Manyama, Simon E Koele, et al.
Nanoimpact|July 26, 2024
Next Generation Risk Assessment approaches for advanced nanomaterials: Current status and future perspectivesDanail Hristozov, Elena Badetti, Paolo Bigini, et al.
Nature Cancer|March 11, 2026
Impact of using artificial intelligence as a second reader in breast screening including arbitrationLucy M Warren, Jenny Venton, Kenneth C Young, et al.
Pageof 13